CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024  MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults. The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufact

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the American College of Cardiology annual meeting (ACC25), to be held March 29th to 31st, 2025 in Chicago, Illinois. "This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhythm. Further, the data showed that conversion of earlier episodes was predictive of conversion

FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to commercialize upon approval with royalty financing MONTREAL and CHARLOTTE, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a regulatory and corporate update. "We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT," said Joseph Oliveto,

MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 94,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of four new hires.  The Options have a grant date of March 3, 2025, and an exercise price of $1.65 per share, which is equal to the closing price of Milestone's common shares on the grant date. The shares subject

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th Annual Health Care Conference, to take place from March 3-5, 2025 in Boston. A live webcast of the fireside chat will be available to conference participants on March 4th at 9:10 AM EST. The webcast is available to watch both live and replay for approximately 90-days following the presentation in the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative

MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) on a new Method of Use patent for etripamil nasal spray (proposed trade name CARDAMYST™), its lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT). The patent, once issued on U.S. Patent Application No.: 17/865,697, covers the repeat dose regimen used in the RAPID Phase 3 study that evaluated CARDAMYST in PS

MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced further details on its in-person and virtual Commercial Launch Plan investor event to take place in New York on Tuesday, February 25, 2025 from 10:30 AM to 12:30 PM ET. Investors planning to attend the in-person event are required to register in advance. To register, click here. Featuring presentations by Joseph Oliveto, President and Chief Executive Officer, and Lorenz Muller, Chief Commercial Officer, the event will provide an overview of Mileston

- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025 - Plans to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE, N.C., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today provided a corporate update and outlined its strategic priorities for 2025. "2025 is set to be a transformative year for Milestone as we prepare for potential FDA approval of CARDAMYS

MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 113,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.  The Options have a grant date of January 2, 2025 and an exercise price of $2.17 per share, which is equal to the closing price of Milestone's common shares on the grant date. The shares subjec

MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time. A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the Milestone team during the conference, email corporateaccess@psc.com. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a biopharmaceutical company developing and com

Rodman & Renshaw initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $9.00

Jefferies downgraded Milestone Pharmaceuticals from Buy to Hold and set a new price target of $4.00 from $8.00 previously

Piper Sandler upgraded Milestone Pharmaceuticals from Neutral to Overweight and set a new price target of $10.00 from $8.00 previously

HC Wainwright initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $20.00

H.C. Wainwright initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $20.00

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

424B5 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

S-8 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

10-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

SCHEDULE 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

EFFECT - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

-       RAPID topline data readout remains on track for mid-second half 2022 -       Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update. "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said Josep

-       RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a clinical and corporate update. "2021 was a year of focused execution across our ongoing clinical programs which are evaluating etripamil in patients with PSVT and AFib-RVR," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We are well-positioned for a transformat

MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of global drug development and clinical experience across a range of therapeutic areas, with a focus on cardiovascular medicine. He will replace Francis Plat, M.D., who will transition to Chief Scientific Officer of the Company and, following the completion of the Phase

MONTREAL, Feb. 14, 2022 /CNW Telbec/ - Find Therapeutics Inc. ('Find') is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer. Dr. Douville brings to Find 25 years of sector experience, with involvement in a number of biotech ventures across the areas of cardiovascular, inflammation, and genomics. He was the founding CEO of Milestone Pharmaceuticals Inc. (NASDAQ:MIST), and led the company for a dozen years from early discovery through to a successful Phase II study, and then contributed to its Nasd

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update. "We are keenly focused on executing on our etripamil development program for patients with PSVT following clear regulatory guidance in the second half of 2020 and commencement of the pivotal Phase 3 RAPID study," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We believe that etripamil has the pot

New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the third quarter ended Septem

-  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes -  Data featured in an oral session at the Heart Rhythm 2023 Annual Meeting -  Company to host virtual KOL conference call and webcast to discuss etripamil development for the treatment of AFib-RVR today at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 22, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experien

-  Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD -  Conference call and webcast on Monday, May 22, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the potential treatment of patients with atrial fibrillation (AFib) and rapid ventricular rate (A

Conference call and webcast on Tuesday, December 6, 2022 at 1:00 p.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 29, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). To access a live or recorded webcast of the event and acc

─     Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001) ─     Consistent safety and tolerability data support potential self-administration of etripamil ─     Analyses of pooled data show statistically significant reduction in medical interventions and visits to the emergency department ─     Company plans to submit an NDA to the U.S. FDA in mid-2023 ─     Conference call and webcast to be held today at 8:00 a.m. Eastern Time MONTREAL and CHARLOTTE, N.C., Oct. 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13D - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)